Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

By sjmartinez • January 22, 2025

Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park YH, Fernandez MG, Rubovszky G, Spring L, Im SA, Hui R, Takano T, André F, Yasojima H, Ding Y, Jia L, Karantza V, Tryfonidis K, Bardia A. Pembrolizumab and chemotherapy in high-risk, early-stage, ER⁺/HER2^- breast cancer: a randomized phase 3 trial. Nat Med. 2025 Jan 21. doi: 10.1038/s41591-024-03415-7. Epub ahead of print. PMID: 39838117.

Tags: Hematology/Oncology, Publications

Novel Endocrine Therapies: Current Status and Future Directions

Brierley-Green E, Duggirala N, McCann KE, Callahan R, Bardia A, Lipsyc-Sharf M. Novel Endocrine Therapies: Current Status and Future Directions. Clin Breast Cancer. 2026 Aug[...]

Insights on supplement use during cancer care from online Reddit conversations

Waissengrin B, O'Connor K, Shirazipour CH, Ivan FA, Reckamp KL, Gonzalez-Hernandez G, Figueiredo JC. Insights on supplement use during cancer care from online Reddit conversations.[...]

Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy

Chan BL, Iguh C, Hwang A, Huang C. Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy. Cureus. 2026 Jul 21;18(7):e113113. doi:[...]